226 related articles for article (PubMed ID: 30604643)
1. A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions.
Neiveyans M; Melhem R; Arnoult C; Bourquard T; Jarlier M; Busson M; Laroche A; Cerutti M; Pugnière M; Ternant D; Gaborit N; Chardès T; Poupon A; Gouilleux-Gruart V; Pèlegrin A; Poul MA
MAbs; 2019 Apr; 11(3):593-605. PubMed ID: 30604643
[TBL] [Abstract][Full Text] [Related]
2. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma.
Shimosaki S; Nakahata S; Ichikawa T; Kitanaka A; Kameda T; Hidaka T; Kubuki Y; Kurosawa G; Zhang L; Sudo Y; Shimoda K; Morishita K
Biochem Biophys Res Commun; 2017 Mar; 485(1):144-151. PubMed ID: 28189691
[TBL] [Abstract][Full Text] [Related]
3. Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents.
Candelaria PV; Leoh LS; Penichet ML; Daniels-Wells TR
Front Immunol; 2021; 12():607692. PubMed ID: 33815364
[TBL] [Abstract][Full Text] [Related]
4. Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1.
Leoh LS; Daniels-Wells TR; Martínez-Maza O; Penichet ML
Mol Immunol; 2015 Oct; 67(2 Pt B):407-15. PubMed ID: 26232328
[TBL] [Abstract][Full Text] [Related]
5. Blood-brain barrier transport using a high affinity, brain-selective VNAR antibody targeting transferrin receptor 1.
Stocki P; Szary J; Rasmussen CLM; Demydchuk M; Northall L; Logan DB; Gauhar A; Thei L; Moos T; Walsh FS; Rutkowski JL
FASEB J; 2021 Feb; 35(2):e21172. PubMed ID: 33241587
[TBL] [Abstract][Full Text] [Related]
6. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
7. Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas.
Crépin R; Goenaga AL; Jullienne B; Bougherara H; Legay C; Benihoud K; Marks JD; Poul MA
Cancer Res; 2010 Jul; 70(13):5497-506. PubMed ID: 20530676
[TBL] [Abstract][Full Text] [Related]
8. Targeting TfR1 with the ch128.1/IgG1 Antibody Inhibits EBV-driven Lymphomagenesis in Immunosuppressed Mice Bearing EBV
Martínez LE; Daniels-Wells TR; Guo Y; Magpantay LI; Candelaria PV; Penichet ML; Martínez-Maza O; Epeldegui M
Mol Cancer Ther; 2021 Sep; 20(9):1592-1602. PubMed ID: 34158342
[TBL] [Abstract][Full Text] [Related]
9. Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells.
Rodríguez JA; Luria-Pérez R; López-Valdés HE; Casero D; Daniels TR; Patel S; Avila D; Leuchter R; So S; Ortiz-Sánchez E; Bonavida B; Martínez-Maza O; Charles AC; Pellegrini M; Helguera G; Penichet ML
Leuk Lymphoma; 2011 Nov; 52(11):2169-78. PubMed ID: 21870996
[TBL] [Abstract][Full Text] [Related]
10. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies.
Sioud M; Westby P; Vasovic V; Fløisand Y; Peng Q
FASEB J; 2018 Sep; 32(9):5063-5077. PubMed ID: 29913558
[TBL] [Abstract][Full Text] [Related]
11. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
Clynes RA; Towers TL; Presta LG; Ravetch JV
Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
[TBL] [Abstract][Full Text] [Related]
13. Development of a complete human anti-human transferrin receptor C antibody as a novel marker of oral dysplasia and oral cancer.
Nagai K; Nakahata S; Shimosaki S; Tamura T; Kondo Y; Baba T; Taki T; Taniwaki M; Kurosawa G; Sudo Y; Okada S; Sakoda S; Morishita K
Cancer Med; 2014 Aug; 3(4):1085-99. PubMed ID: 24890018
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies.
Liu C; Yu C; Yang Y; Huang J; Yu X; Duan M; Wang L; Wang J
Int Immunopharmacol; 2021 Nov; 100():108112. PubMed ID: 34521023
[TBL] [Abstract][Full Text] [Related]
16. An IgG1 Version of the Anti-transferrin Receptor 1 Antibody ch128.1 Shows Significant Antitumor Activity Against Different Xenograft Models of Multiple Myeloma: A Brief Communication.
Daniels-Wells TR; Candelaria PV; Leoh LS; Nava M; Martínez-Maza O; Penichet ML
J Immunother; 2020; 43(2):48-52. PubMed ID: 31693515
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of an Anti-transferrin Receptor 1 Antibody Against AIDS-related Non-Hodgkin Lymphoma: A Brief Communication.
Daniels-Wells TR; Widney DP; Leoh LS; Martínez-Maza O; Penichet ML
J Immunother; 2015 Oct; 38(8):307-10. PubMed ID: 26325374
[TBL] [Abstract][Full Text] [Related]
18. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.
Leoh LS; Kim YK; Candelaria PV; Martínez-Maza O; Daniels-Wells TR; Penichet ML
J Immunol; 2018 May; 200(10):3485-3494. PubMed ID: 29654211
[TBL] [Abstract][Full Text] [Related]
20. The transgenic chicken derived anti-CD20 monoclonal antibodies exhibits greater anti-cancer therapeutic potential with enhanced Fc effector functions.
Kim YM; Park JS; Kim SK; Jung KM; Hwang YS; Han M; Lee HJ; Seo HW; Suh JY; Han BK; Han JY
Biomaterials; 2018 Jun; 167():58-68. PubMed ID: 29554481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
